MedTrace Logo

A Trial of SHR-1210 in Combination With AIN457 in Patients With MSS CRC（SHR-1210-AIN457）

NCT04298320 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2020-03-16

No results posted yet for this study

Summary

This is a Phase Ib/IIa, Open-label, Investigator-initiated Trail of SHR-1210 (an Anti-PD-1 Inhibitor) in combination with AIN457 for patients with late stage MSS CRC who failed second-line and above treatment.

The main purpose of this study is to evaluate the safety, tolerability and RD of SHR-1210 combination with AIN457 as a treatment of MSS CRC.

Conditions

Interventions

DRUG

SHR-1210

SHR-1210 was administered 200mg iv every 2 weeks

DRUG

AIN 457

AIN457 was administered 150mg or 300mg ih every 2 weeks

Sponsors & Collaborators

  • Yanqiao Zhang

    lead OTHER

Principal Investigators

  • Yanqiao Zhang, PhD · Harbin Medical University Cancer Hosptital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-15
Primary Completion
2022-02-28
Completion
2023-02-28

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04298320 on ClinicalTrials.gov